Get it on Google Play

ProMIS Neurosciences advances to final dose cohort in alzheimer's trial

September 3, 2025 7:00 AM EDT Send to a Friend
ProMIS Neurosciences Inc. (NASDAQ: PMN) announced that an independent Data and Safety Monitoring Board has approved the company's progression to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login